The potential therapeutic effects of THC on Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 42, Issue 3, 2014, Pages 973-984

  Cao, Chuanhai ^a   Li, Yaqiong ^b   Liu, Hui ^a   Bai, Ge ^b   Mayl, Jonathan ^a   Lin, Xiaoyang ^a   Sutherland, Kyle ^c   Nabar, Neel ^d   Cai, Jianfeng ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; amyloid peptide; cannabinoid; CB1 receptor; CB2 receptor; delta(9) tetrahydrocannabinol; neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN; CAFFEINE; CANNABINOID 1 RECEPTOR; DRONABINOL; GLYCOGEN SYNTHASE KINASE 3BETA; MELATONIN; THIOFLAVINE; AMYLOID PRECURSOR PROTEIN; CANNABINOID RECEPTOR AGONIST; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; BRAIN MITOCHONDRION; BRAIN NERVE CELL; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME PHOSPHORYLATION; MTT ASSAY; PROTEIN AGGREGATION; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; CELL RESPIRATION; DOSE RESPONSE; DRUG EFFECTS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; MOUSE; MUTATION; NEUROBLASTOMA; PATHOLOGY; PHOSPHORYLATION; TUMOR CELL LINE;

AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; CANNABINOID RECEPTOR AGONISTS; CELL LINE, TUMOR; CELL RESPIRATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; MICE; MITOCHONDRIA; MUTATION; NEUROBLASTOMA; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAU PROTEINS; TRANSFECTION;

EID: 84907146173     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-140093     Document Type: Article

References (42)

1. Alzheimer's, Association (2012) 2012 Alzheimer's disease facts and figures. Alzheimers Dement 8, 131-168.
2. Saxena U (2011) Bioenergetics breakdown in Alzheimer's disease: Targets for new therapies. Int J Physiol Pathophysiol Pharmacol 3, 133-139.
3. Götz J, Eckert A, Matamales M, Ittner LM, Liu X (2011) Modes of A-toxicity in Alzheimer's disease. Cell Mol Life Sci 68, 3359-3375.
4. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191.
5. Chiti F, Dobson CM (2006) Protein misfolding, functional amyloid, and human disease. Annu Rev Biochem 75, 333-366.
6. Campbell V, Gowran A(2007) Alzheimer's disease; taking the edge off with cannabinoids? Br J Pharmacol 152, 655-662.
7. Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C, Brandt J (1995) Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology 45, 51-55.
8. Octave JN (1995) The amyloid peptide and its precursor in Alzheimer's disease. Rev Neurosci 6, 287-316.
9. Reitz C, Brayne C, Mayeux R (2011) Epidemiology of Alzheimer disease. Nat Rev Neurol 7, 137-152.
10. Pillay N, Kellaway L, Kotwal G (2004) Molecular mechanisms, emerging etiological insights and models to test potential therapeutic interventions in Alzheimer's disease. Curr Alzheimer Res 1, 295-306.
11. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439.
12. Proctor CJ, Gray DA (2010) GSK3 and p53-is there a link in Alzheimer's disease? Mol Neurodegener 5, 7.
13. Lovestone S, Reynolds CH, Latimer D, Davis DR, Anderton BH, Gallo JM, Hanger D, Mulot S, Marquardt B, Stabel S, et al. (1994) Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol 4, 1077-1086.
14. Ishiguro K, Omori A, Takamatsu M, Sato K, Arioka M, Uchida T, Imahori K (1992) Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci Lett 148, 202-206.
15. Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH (1992) Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett 147, 58-62.
16. Cho JH, Johnson GV (2003) Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem 278, 187-193.
17. Asuni AA, Hooper C, Reynolds CH, Lovestone S, Anderton BH, Killick R (2006) GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt In. Eur J Neurosci 24, 3387-3392.
18. Hernandez F, Lucas JJ, Avila J (2013) GSK3 and tau: Two convergence points in Alzheimer's disease. J Alzheimers Dis 33(Suppl 1), S141-S144.
19. Engel T, Goni-Oliver P, Lucas JJ,Avila J, Hernandez F (2006) Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 99, 1445-1455.
20. Phiel CJ,Wilson CA, Lee VM, Klein PS (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 423, 435-439.
21. Sun X, Sato S, Murayama O, Murayama M, Park JM, Yamaguchi H, Takashima A (2002) Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 321, 61-64.
22. DaRocha-Souto B, Coma M, Perez-Nievas BG, Scotton TC, Siao M, Sanchez-Ferrer P, Hashimoto T, Fan Z, Hudry E, Barroeta I, Sereno L, Rodriguez M, Sanchez MB, Hyman BT, Gomez-Isla T (2012) Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis 45, 425-437.
23. Jackson SJ, Diemel LT, Pryce G, Baker D (2005) Cannabinoids and neuroprotection in CNS inflammatory disease. J Neurol Sci 233, 21-25.
24. Riedel G, DaviesSN(2005) Cannabinoid function in learning, memory and plasticity. Handb Exp Pharmacol 445-477.
25. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA (2005) Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 310, 329-332.
26. Ashton JC, Friberg D, Darlington CL, Smith PF (2006) Expression of the cannabinoid CB2 receptor in the rat cerebellum: An immunohistochemical study. Neurosci Lett 396, 113-116.
27. Nunez E, Benito C, Pazos MR, Barbachano A, Fajardo O, Gonzalez S, Tolon RM, Romero J (2004) Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study. Synapse 53, 208-213.
28. Marchalant Y, Brothers H, Norman G, Karelina K, DeVries A,WenkG(2009) Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis. Neurobiol Dis 34, 300-307.
29. Ramrez B, Blázquez C, Gómez del Pulgar T, Guzmán M, de Ceballos M(2005) Prevention of Alzheimer's disease pathology by cannabinoids: Neuroprotection mediated by blockade of microglial activation. J Neurosci 25, 1904-1913.
30. Benito C, Nunez E, Tolon RM, Carrier EJ, Rabano A, Hillard CJ, Romero J (2003) Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J Neurosci 23, 11136-11141.
31. Martn-Moreno AM, Reigada D, Ramrez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML (2011) Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: Relevance to Alzheimer's disease. Mol Pharmacol 79, 964-973.
32. Bisogno T, Di Marzo V (2010) Cannabinoid receptors and endocannabinoids: Role in neuroinflammatory and neurodegenerative disorders. CNS Neurol Disord Drug Targets 9, 564-573.
33. Piomelli D (2003) The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 4, 873-884.
34. Volicer L, Stelly M, Morris J, McLaughlin J,Volicer BJ (1997) Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease. Int J Geriatr Psychiatry 12, 913-919.
35. Walther S, Mahlberg R, Eichmann U, Kunz D (2006) Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. Psychopharmacology (Berl) 185, 524-528.
36. Mishra S, Mishra M, Seth P, Sharma SK (2011) Tetrahydrocurcumin confers protection against amyloid-induced toxicity. Neuroreport 22, 23-27.
37. Cao C, Loewenstein DA, Lin X, Zhang C,Wang L, Duara R, Wu Y, Giannini A, Bai G, Cai J, Greig M, Schofield E, Ashok R, Small B, Potter H, Arendash GW (2012) High blood caffeine levels in MCI linked to lack of progression to dementia. J Alzheimers Dis 30, 559-572.
38. Dragicevic N, Copes N, O'Neal-Moffitt G, Jin J, Buzzeo R, Mamcarz M, Tan J, Cao C, Olcese JM, Arendash GW, Bradshaw PC (2011) Melatonin treatment restores mitochondrial function in Alzheimer's mice:Amitochondrial protective role of melatonin membrane receptor signaling. J Pineal Res 51, 75-86.
39. Cao C, Cirrito J, Lin X,Wang L, Verges D, Dickson A, Mamcarz M, Zhang C, Mori T, Arendash G, Holtzman D, Potter H (2009) Caffeine suppresses amyloid-beta levels in plasma and brain of Alzheimer's disease transgenic mice. J Alzheimers Dis 17, 681-697.
40. Agadjanyan MG, Ghochikyan A, Petrushina I, Vasilevko V, Movsesyan N, Mkrtichyan M, Saing T, Cribbs DH (2005) Prototype Alzheimer's disease vaccine using the immunodominantBcell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol 174, 1580-1586.
41. Arendash G, CaoC(2010) Caffeine and coffee as therapeutics against Alzheimer's disease. J Alzheimers Dis 20(Suppl 1), S117-S126.
42. Nakamura EM, da Silva EA, Concilio GV, Wilkinson DA, Masur J (1991) Reversible effects of acute and long-term administration of delta-9-tetrahydrocannabinol (THC) on memory in the rat. Drug Alcohol Depend 28, 167-175.